Posterior Reversible Encephalopathy Syndrome
NEJM 388:2171-2178, Geocadin,R.G., 2023
A 59-Year-Old Woman Presenting with Diplopia, Dysarthria, Right-sided Weakness, and Encephalopathy
Neurol 97:e859-e864, Manzano, G.S.,et al, 2021
Intracranial Neoplasms and Paraneoplastic Disorders, Oligodendroglioma
Adams & Victors Principles of Neurology, Chp 31, pg 654, Ropper, A.H.,et al, 2014
Clinicopathologic Conference, Glioblastonoma, WHO grade IV of IV, with Methylation of the MGMT Promoter
NEJM 366:2112-2120, Case 17-2012, 2012
Current Concepts and Management of Glioblastoma
Ann Neurol 70:9-21, Preusser, M.,et al, 2011
Clinicopath Conf, Intravascular Large-B-Cell Lympoma
NEJM 362:1129-1138, Case 9-2010, 2010
Primary Central Nervous System Post-Transplantation Lymphoproliferative Disorder
CANCER 16:863-870, Cavaliere, R.,et al, 2010
Delayed Leukoencephalopathy with Stroke-Like Presentation in Chemotherapy Recipients
JNNP 79:535-539, Baehring,J.M. &Fulbright,R.K., 2008
Age and High-Dose Methotrexate are Associated to Clinical Acute Encephalopathy in FRALLE 93 Trial for Acute Lymphoblastic Leukemia in Children
Leukemia 21:238-247, Dufourg, M.N.,et al, 2007
Acute Methotrexate Neurotoxicity: Findings on Diffusion-Weighted Imaging and Correlation with Clinical Outcome
AJNR 25:1688-1695, Rollins,N.,et al, 2004
Atypical manifestations of reversible posterior leukoencephalopathy syndrome: findings on diffusion imaging and ADC mapping
Nueroradiology 46:978-983, Ahn, K.J.,et al, 2004
Biochemical And Clinical Aspects of Methotrexate Neurotoxicity
Chemotherapy 49:92-104, Vezmar,S.,et al, 2003
Neurotoxocity of Intrathecal Methotrexate: MR Imaging Findings
AJNR 24:1887-1890, Sandoval,C.,et al, 2003
Clinicopath Conf,Multifocal Inflammatory Leukoencephalopathy Related to Combination Chemo with Fluorouracil/levamisole
NEJM 341:512-519, Case 24-1999, 1999
Cisplatin Neurotoxicity Presenting as Reversible Posterior Leukoencephalopathy Syndrome
AJNR 19:415-417, 5911998., Ito,Y.,et al, 1998
Neurologic Emergencies in Cancer Patients
Neurol Clin 16:1-37, Schiff,D.,et al, 1998
A Reversible Posterior Leukoencephalopathy Syndrome
NEJM 334:494-500, Hinchey,J.,et al, 1996
Transient Ara-C Leukoencephalopathy:MR Findings
J Comput Assist Tomogr 20:161-169, Patel,A.G.&Rao,R., 1996
Reversible MRI Abnormalities Following Seizures
Neurol 45:104-108, Yaffe,K.,et al, 1995
Primary Brain Tumors:Review of Etiology Diagnosis and Treatment
Am Fam Physician 49:787-797, Newton,H.B., 1994
Multifocal Inflammatory Leukoencephalopathy with 5-Fluorouracil and Levamisole
Ann Neurol 31:262-267, Hook,C.C.,et al, 1992
Central Nervous System Toxicity with High-Dose Ara-C
Neurol 35:1475-1479, Hwang,T.,et al, 1985
Reversible Central Nervous System Dysfunction Due to Tamoxifen in a Patient with Breast Cancer
Ann Int Med 101:652, Pluss,J.L.,et al, 1984
Cerebellar Degeneration Caused by High-Dose Cytosine Arabinoside:A Clinicopathological Study
Ann Neurol 14:520-527, Winkelman,M.D.,et al, 1983
Neurotoxic Effects of Cisplatin Therapy
Arch Neurol 39:719-720, Walsh,T.J.,et al, 1982
Nervous System Toxicity of Chemo Agents
Young, DF, in Vinken PJ, Bruyn GW, Handbook of Clin Neurol, North-Holland Publ Co, Amster, Vol 39, 1, 80, p 104, 1980
Malignant Optic Gliomas in Adults
Arch Neurol 35:731-735, Harper,C.G.,et al, 1978
Neurotoxicity of Commonly Used Antineoplastic Agents
NEJM 291:75, 1271974., Weiss,H.,et al, 1974
Infiltration of the Leptomeninges by Systemic Cancer:a Clinical & Pathologic Study
Arch Neurol 30:122, Olson,M.E.,et al, 1974
Neurological Complications of Systemic Cancer
Med Clin North Am 55:625, Posner,J., 1971